The Filing Desk

uniQure

QURE · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

QURE · Last close · November 19, 2026
$20.23
Value uniQure yourself

uniQure's revenue fell 40.6% to $16 million in fiscal 2025. Its operating margin was −1,151.4%, down from −679.6% a year earlier. Free cash flow was −$178 million. The diluted share count rose 18.2%.

uniQure N.V. Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001104659-26-021898 Updated
Revenue
$16M
40.6%
Operating margin
−1,151.4%
471.8 pts
Net income
−$199M
 
Free cash flow
−$178M
 
Return on equity
−207.1%
31.4 pts
Market cap
$1.4B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Diluted earnings per share for fiscal 2017 to 2018 is left blank: the filing's figure is far from net income divided by diluted shares, so one of them is in the wrong units.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

uniQure lost money in fiscal 2025: a net loss of $199 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments55622824115980
Debt incl. finance leases1361441486672
Net debt (negative means net cash)−421−84−94−93−8
Net debt to EBITDA−1.3x————
Debt to equity0.2x0.3x0.7x—0.4x
Interest coverage41.6x−12.2x−6.8x−2.9x−3.0x
Current ratio17.1x6.3x8.8x9.7x10.4x
Quick ratio17.1x6.2x8.7x—10.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project uniQure's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought uniQure shares on the open market, and 8 insiders sold $19.8 million, $17.8 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jul 2, 2026Matthew C KapustaCEO, Managing Director, DirectorSold plan21,082$45.16$952,051Form 4
Jun 30, 2026Walid Abi-SaabChief Medical OfficerSold plan30,000$46.42$1.4 millionForm 4
Jun 30, 2026Jack KayeDirectorSold plan21,167$46.44$983,030Form 4
Jun 26, 2026Walid Abi-SaabChief Medical OfficerSold1,434$46.86$67,197Form 4
Jun 25, 2026Matthew C KapustaCEO, Managing Director, DirectorSold plan28,716$50.02$1.4 millionForm 4
Jun 24, 2026Matthew C KapustaCEO, Managing Director, DirectorSold plan6,696$50.00$334,800Form 4
Jun 18, 2026Matthew C KapustaCEO, Managing Director, DirectorSold plan41,671$50.00$2.1 millionForm 4
Jun 17, 2026Matthew C KapustaCEO, Managing Director, DirectorSold plan164,429$44.32$7.3 millionForm 4
Jun 17, 2026Madhavan BalachandranDirectorSold plan11,685$45.06$526,485Form 4
Jun 17, 2026Jack KayeDirectorSold plan5,295$42.57$225,408Form 4
Jun 15, 2026Madhavan BalachandranDirectorSold plan10,000$27.85$278,500Form 4
Jun 15, 2026Jeannette PottsChief Legal OfficerSold5,237$27.67$144,908Form 4
The latest 12 of 30 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 95 of 92 of 9
Rule of 40−1,051.4%−615.0%−1,148.9%
Altman Z''−0.87−4.73−1.71
Accruals ratio−21.2%−8.2%−3.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rosePassFailFail
Revenue rose relative to assetsFailPassFail
F-score3 of 95 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put uniQure side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
uniQureFY25−40.6%−1,151.4%−1,108.2%——2
Relay TherapeuticsFY2553.4%−1,971.6%−1,536.1%———Compare
MediWoundFY25−16.1%−149.0%−127.5%———Compare
Lineage Cell TherapeuticsFY2553.2%−251.6%−133.6%———Compare
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue251311738524106162716
Revenue growth137.3%−47.8%−13.9%−35.5%415.2%1,296.8%−79.7%−85.1%71.2%−40.6%
Gross profit241210635499105162614
Research and development72727595122144198215144141
Operating income−72−71−88−121−125311−143−283−184−185
Net income−73−79−83−124−125330−127−308−240−199
Diluted EPS (US$)−2.93——−3.11−2.817.04−2.71−6.47−4.92−3.46
Diluted shares (millions)25273640444747484958
Cash flow
Cash from operations−72−64−76−99−135288−145−146−183−178
Capital expenditure1542671718730
Free cash flow−87−69−78−104−142271−163−153−186−178
Dividends paid0000000000
Share buybacks0000000000
Acquisitions00000502000
Stock-based compensation6101118222634352218
Balance sheet at fiscal year end
Cash and short-term investments13215923537824555622824115980
Debt incl. finance leases20244846421361441486672
Total assets190210274449340809705832556825
Total liabilities1271209412696213229624563626
Shareholders' equity6489180323244596476208−7199
Margins and ratios
Gross margin94.6%93.8%89.3%77.3%92.3%95.2%98.8%99.6%95.3%89.5%
Operating margin−286.7%−544.3%−781.9%−1,663.8%−334.3%59.3%−134.4%−1,785.5%−679.6%−1,151.4%
Net margin−292.4%−604.7%−738.2%−1,705.8%−333.3%62.9%−119.1%−1,947.1%−883.4%−1,236.0%
Free cash flow margin−348.5%−524.4%−695.0%−1,433.0%−378.8%51.6%−152.8%−966.2%−686.2%−1,108.2%
Rule of 40 (growth + FCF margin)−211.3%−572.2%−708.9%−1,468.5%36.4%1,348.4%−232.5%−1,051.4%−615.0%−1,148.9%
Return on capital—————284.2%−39.9%−88.3%——
Return on equity−76.6%−103.6%−61.9%−49.4%−44.1%78.5%−23.7%−90.2%−238.5%−207.1%
Return on assets−32.4%−39.6%−34.5%−34.4%−31.7%57.3%−16.8%−40.1%−34.5%−28.8%
Net debt to EBITDA—————−1.3x————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: uniQure's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with uniQure.